ArticleCancer research2025
tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer Progression.
Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- tRNA-derived small RNAs in tumor microenvironment remodeling: From mechanistic insights to therapeutic perspectives.Oncogene · 2026Review
- Macrophage membrane-biomimetic nanovehicles delivering amygdalin halt pyroptosis propagation and alleviate endometriosis-associated neuropathic pain.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Transfer RNA-derived fragments (tRF) are a class of small noncoding RNAs that have recently been implicated in various physiologic and pathologic processes, including tumor development and progression. Identification of the roles of tRFs in cancer could provide insights into tumor biology and treatment strategies. In this study, we found that tRF-21LeuTAA (tRF-21) supported the progression of prostate cancer by regulating glutathione metabolic enzymes and promoting reactive oxygen species (ROS) accumulation. Nuclear tRF-21 upregulated leucyl aminopeptidase 3 (LAP3) by binding to its promoter and recruiting H3K27ac acetyltransferase P300 and transcription factor STAT1. The increased cystine-glycine dipeptidase activity of LAP3 led to increased degradation of the antioxidant glutathione. Alternatively, cytoplasmic tRF-21 suppressed glutathione S-transferase mu 3 by repressing its mRNA posttranscriptionally, which further elevated ROS by decreasing scavenger glutathione S-transferase activity. The accumulation of intracellular ROS downstream of tRF-21-mediated alterations in LAP3 and glutathione S-transferase mu 3 resulted in AKT activation. Overexpression of tRF-21 promoted the proliferation and migration of prostate cancer cells, formation of spheroids, and initiation and growth of tumors in a xenograft model. In patients, elevated tRF-21 and LAP3 levels were associated with unfavorable survival outcomes. The regulatory circuitry revealed in the present study may represent potential therapeutic targets for prostate cancer as well as various malignancies with tRF-21 overexpression. SIGNIFICANCE: tRF-21 promotes tumor development by disrupting key metabolic, epigenetic, transcriptional, and post-transcriptional processes that converge on increased oxidative stress, suggesting that targeting this axis may benefit malignancies with elevated tRF-21.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.